DEA Shuts Down Florida Addiction Center Over Expired Licenses
Published Date: 8/28/2026
Notice
Summary
The DEA has officially shut down Atlantic Treatment Center in Florida because it lost its state license and federal certification to treat substance use disorders. This means the center can no longer operate legally, protecting public health and safety. The center’s DEA registration expired on June 30, 2026, and this decision finalizes the revocation, making it clear no more services can be offered.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for Treatment Center
The Drug Enforcement Administration revoked DEA Certificate of Registration No. RA0645400 issued to Atlantic Treatment Center, LLC. Atlantic Treatment Center (Pompano Beach, Florida) currently lacks state licensure and SAMHSA certification and is unable to dispense controlled substances for detoxification treatment; the revocation is effective September 28, 2026.
Pending Renewal/Registration Applications Denied
The DEA also denies any pending applications from Atlantic Treatment Center, LLC to renew or modify DEA Certificate No. RA0645400 and denies any other pending application for additional registration in Florida. That denial is part of the Agency's final order, effective September 28, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20749, Vladimir Romaniv, P.A.; Decision and Order
The DEA has officially suspended and is moving to revoke Vladimir Romaniv, P.A.'s registration because he gave multiple prescriptions without properly checking on a patient who was in jail. This affects Romaniv’s ability to prescribe controlled substances and signals serious legal trouble starting from late 2025. If you’re connected to his practice or rely on his prescriptions, expect changes and tighter controls soon.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
Previous / Next Documents
Previous: 2026-17593, Agency Information Collection Extension Without Changes
EIA invites public comment on the proposed three-year extension, without changes, to Form EIA-846 Manufacturing Energy Consumption Survey Report as required under the Paperwork Reduction Act of 1995. The report is part of EIA's comprehensive energy data program. Form EIA-846 Manufacturing Energy Consumption Survey Report (quadrennial) collects information on energy consumption, expenditures, and building characteristics from establishments in the manufacturing sector.
Next: 2026-17595, Rescission Notice; St. Johns Watershed Project in Mississippi, New Madrid, and Scott Counties, Missouri
The NRCS Missouri State Office, in coordination with the St. Johns Levee and Drainage District of Southeast Missouri, is rescinding the Notice of Intent (NOI) to prepare an Environmental Impact Statement (EIS) for the St. Johns Watershed Project in Mississippi, New Madrid, and Scott Counties, Missouri, which was published in the Federal Register on August 13, 2025. NRCS has determined that the NOI was issued prior to confirming the need for an EIS.